WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Wuxi Biologics Co. Ltd. is licensing a preclinical trispecific T-cell engager to Candid Therapeutics Inc. in a deal worth up to $925 million plus royalties.

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

Current health news includes Trump considering protective measures for gas appliances against regulatory changes. The WHO ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

Find insight on China’s healthcare sector, Wuxi Biologics and more in the latest Market Talks covering the Health Care sector ...